Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherBasic Science (Animal or Phantoms)

18F-FAraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy

Jelena Levi, Samuel Goth, Lyna Huynh, Tina Lam, Tony L Huynh, Brailee Schulte and Juliet A Packiasamy
Journal of Nuclear Medicine November 2020, jnumed.120.249078; DOI: https://doi.org/10.2967/jnumed.120.249078
Jelena Levi
1 CellSight Technologies, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Goth
1 CellSight Technologies, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lyna Huynh
1 CellSight Technologies, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tina Lam
1 CellSight Technologies, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tony L Huynh
2 UCSF Department of Radiology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brailee Schulte
3 UCSF Department of Radiology and Biomedical Imaging
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juliet A Packiasamy
1 CellSight Technologies, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Majority of the clinical trials exploring various combinations of chemo- and immunotherapy rely on serial biopsy to provide information on immune response. The aim of this study was to assess the value of 18F-FAraG as a non-invasive tool that could profile tumors based on the key players in adaptive antitumor response, CD8+ cells, and evaluate immunomodulatory effects of chemotherapy. Methods: To evaluate the ability of 18F-FAraG to report on the presence of CD8+ cells within the TME, we imaged a panel of syngeneic tumor models (MC38, CT26, LLC, A9F1, 4T1 and B16F10), and correlated the signal intensity with the number of lymphocytes found in the tumors. The capacity of 18F-FAraG to detect immunomodulatory effects of chemotherapy, was determined by longitudinal imaging of tumor bearing mice (MC38, A9F1) undergoing two types of chemotherapy: oxaliplatin/cyclophosphamide, shown to induce immunogenic cell death and paclitaxel/carboplatin, reported to cause immunogenically silent tumor cell death. Results: 18F-FAraG revealed strikingly different uptake patterns in the tumor panel, which resembled cancer-immune phenotypes observed in the clinic. Statistically significant correlation was found between the 18F-FAraG signal and the number of PD-1 positive CD8+ cells isolated from the tumors (r2=0.528, p<0.0001). In the MC38 model, paclitaxel/carboplatin did not result in appreciable change in signal post therapy (1.69 ± 0.25 vs. 1.50 ± 0.33 %ID/g), but oxaliplatin/cyclophosphamide treatment led to close to 2.4 fold higher 18F-FAraG signal (1.20 ± 0.31 vs. 2.84 ± 0.93 %ID/g). The statistically significant increase in signal post oxaliplatin/cyclophosphamide was also observed in A9F1 model (0.95 ± 0.36 vs.1.99 ± 0.54 %ID/g). Conclusion: The ability of 18F-FAraG PET to assess the location and function of CD8+ cells, as well immune activity within tumors post immune priming therapy warrants further investigation into its utility for patient selection, evaluation of optimal time to deliver immunotherapies, and assessment of combinatorial therapy approaches.

  • CD8 T cells
  • chemotherapy
  • immunomodulation
  • Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (2)
Journal of Nuclear Medicine
Vol. 62, Issue 2
February 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
18F-FAraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
18F-FAraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy
Jelena Levi, Samuel Goth, Lyna Huynh, Tina Lam, Tony L Huynh, Brailee Schulte, Juliet A Packiasamy
Journal of Nuclear Medicine Nov 2020, jnumed.120.249078; DOI: 10.2967/jnumed.120.249078

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
18F-FAraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy
Jelena Levi, Samuel Goth, Lyna Huynh, Tina Lam, Tony L Huynh, Brailee Schulte, Juliet A Packiasamy
Journal of Nuclear Medicine Nov 2020, jnumed.120.249078; DOI: 10.2967/jnumed.120.249078
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Basic Science (Animal or Phantoms)

  • Comparative preclinical biodistribution, dosimetry and endoradiotherapy in mCRPC using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
  • Preclinical evaluation of 213Bi-/225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer
  • Metallo-Fluorocarbon Nanoemulsion for Inflammatory Macrophage Detection via PET and MRI
Show more Basic Science (Animal or Phantoms)

Basic (Oncology: Other)

  • Identification of a PET Radiotracer for Imaging of the Folate Receptor-alpha – A Potential Tool to Select Patients for Targeted Tumor Therapy
Show more Basic (Oncology: Other)

Similar Articles

Keywords

  • CD8 T cells
  • chemotherapy
  • immunomodulation
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire